REGENERATION AND REPAIR OF NEURAL TISSUE FOLLOWING INJURY
First Claim
Patent Images
1. A method of treating a patient having a neurological injury comprising administering to the patient isolated umbilical cord tissue-derived cells in an amount effective to treat the neurological injury, wherein the umbilical cord tissue-derived cells are derived from human umbilical cord tissue substantially free of blood, wherein the cells are capable of self-renewal and expansion in culture and have the potential to differentiate into cells of at least a neural phenotype;
- and, wherein the cells do not express CD117.
2 Assignments
0 Petitions
Accused Products
Abstract
Methods, pharmaceutical compositions and kits for regenerating or repairing neural tissue, decreasing apoptosis and improving neurological function following injury are disclosed.
-
Citations
35 Claims
-
1. A method of treating a patient having a neurological injury comprising administering to the patient isolated umbilical cord tissue-derived cells in an amount effective to treat the neurological injury, wherein the umbilical cord tissue-derived cells are derived from human umbilical cord tissue substantially free of blood, wherein the cells are capable of self-renewal and expansion in culture and have the potential to differentiate into cells of at least a neural phenotype;
- and, wherein the cells do not express CD117.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 15, 16, 17, 18, 19, 21, 22, 23, 24)
-
9. A method of stimulating regeneration capacity of a subventricular zone (SVZ) of a patient comprising administering to the patient isolated umbilical cord tissue-derived cells in an amount effective to increase neurogenesis, angiogenesis, or synaptogenesis, wherein the umbilical cord tissue-derived cells are derived from human umbilical cord tissue substantially free of blood, wherein the cells are capable of self-renewal and expansion in culture and have the potential to differentiate into cells of at least a neural phenotype;
- and, wherein the cells do not express CD117.
- View Dependent Claims (10, 11, 12, 13, 14, 20)
-
25. A pharmaceutical composition for treating a patient having a neurological injury, comprising a pharmaceutically acceptable carrier and isolated umbilical cord tissue-derived cells in an amount effective to treat the neurological injury wherein the umbilical cord tissue-derived cells are derived from human umbilical cord tissue substantially free of blood, wherein the cells are capable of self-renewal and expansion in culture and have the potential to differentiate into cells of at least a neural phenotype;
- and, wherein the cells do not express CD117.
- View Dependent Claims (26, 27, 28, 29)
-
30. A kit for treating a patient having a neurological injury, the kit comprising a pharmaceutically acceptable carrier, a population of isolated umbilical cord tissue-derived cells and instructions for using the kit in a method of treating the patient, wherein the umbilical cord tissue-derived cells are derived from human umbilical cord tissue substantially free of blood, wherein the cells are capable of self-renewal and expansion in culture and have the potential to differentiate into cells of at least a neural phenotype;
- and, wherein the cells do not express CD117.
- View Dependent Claims (31, 32, 33, 34, 35)
Specification